Top

Published in:

01-06-2013 | Educational Series – Red Series

Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Authors: F. J. Afonso, U. Anido, O. Fernández-Calvo, S. Vázquez-Estévez, L. León, M. Lázaro, M. Ramos, L. Antón-Aparicio

Published in: Clinical and Translational Oncology | Issue 6/2013

Abstract

We performed a literature search that shed light on the signaling pathways involved in the sorafenib activity as first- or subsequent-line treatment, taking into account its toxicity profile. Sorafenib appears to have better tolerability when compared with other agents in the same indication. Cross-resistance between tyrosine kinase inhibitors (TKIs) may be limited, even after failure with a previous VEGFR inhibitor, but the optimal sequence with TKIs remains to be determined. Randomized trials of second-line treatment options have showed either modest or no differences in terms of progression-free and overall survival (OS). Direct comparison between sorafenib and axitinib demonstrated differences in terms of PFS in favor of axitinib, but not in terms of OS as second-line treatment. In contrast, a phase III study showed a benefit in OS, favoring sorafenib when compared with temsirolimus. In conclusion, after using other VEGF inhibitor such as sunitinib, sorafenib is active and safe for the treatment of patients with advanced or metastatic RCC.

Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRef

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef

Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318PubMedCrossRef

Bellmunt J, Guix M (2009) The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 103:572–577PubMedCrossRef

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef

Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333–339PubMedCrossRef

Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456PubMedCrossRef

Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265PubMedCrossRef

U.S. Food and Drug Administration (U.S. FDA). INLYTA(R) (Axitinib). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM283657.pdf. Access date: 1 July 2012

10.

Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939PubMedCrossRef

11.

Lowy DR, Willumsen BM (1993) Function and regulation of Ras. Annu Rev Biochem 62:851–891PubMedCrossRef

12.

Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689PubMed

13.

Naumann U, Eisenmann-Tappe I, Rapp UR (1997) The role of Raf kinases in development and growth of tumors. Recent Results Cancer Res 143:237–244PubMedCrossRef

14.

Chong H, Lee J, Guan KL (2001) Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20:3716–3727PubMedCrossRef

15.

Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459–465PubMedCrossRef

16.

Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef

17.

Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934PubMedCrossRef

18.

Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109PubMedCrossRef

19.

Wilhelm S, Housley T, Kennure N (2001) A novel diphenylurea Raf kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells. Proc Am Assoc Cancer Res 42:923

20.

Wilhelm S, Chien DS (2002) BAY 43–9006: preclinical data. Curr Pharm Des 8:2255–2257PubMedCrossRef

21.

Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65–71PubMed

22.

Na X, Wu G, Ryan CK et al (2003) Overproduction of vascular endothelial growth factor related to von Hippel–Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588–592PubMedCrossRef

23.

Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739PubMedCrossRef

24.

Lyons JF, Wilhelm S, Hibner B et al (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219–225PubMedCrossRef

25.

Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965–972PubMedCrossRef

26.

Moore M, Hirte HW, Siu L et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43–9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16:1688–1694PubMedCrossRef

27.

Clark JW, Eder JP, Ryan D et al (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472–5480PubMedCrossRef

28.

Negrier S, Jager E, Porta C et al (2010) Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 27:899–906PubMedCrossRef

29.

Stadler WM, Figlin RA, McDermott DF et al (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116:1272–1280PubMedCrossRef

30.

Beck J, Procopio G, Bajetta E et al (2011) Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22:1812–1823PubMedCrossRef

31.

Dudek AZ, Zolnierek J, Dham A et al (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61–67PubMedCrossRef

32.

Sablin MP, Negrier S, Ravaud A et al (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182:29–34; discussion 34

33.

Vickers MM, Choueiri TK, Rogers M et al (2010) Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76:430–434PubMedCrossRef

34.

Porta C, Procopio G, Carteni G et al (2011) Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 108:E250–E257PubMedCrossRef

35.

Heng DYC, Lee J-L, Harshman LC et al (2012) A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 30:387

36.

Kontovinis L, Laschos K, Karadimou A et al (2012) Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Med Oncol 29:750–754PubMedCrossRef

37.

Rini BI, Escudier BJ, Michaelson MD et al (2012) Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. ASCO Meeting Abstracts 30:354

38.

Gore ME, Jones RJ, Ravaud A et al (2011) Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 29:4609

39.

Hutson TE, Escudier B, Esteban E et al (2012) Temsirolimus vs. sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Ann Oncol 23(suppl 9):IXE14

40.

Michel MS, Vervenne W, Goebell PJ et al (2012) Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): safety interim analysis results. ASCO Meeting Abstracts 30:4539

41.

Garcia JA, Hutson TE, Elson P et al (2010) Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116:5383–5390PubMedCrossRef

42.

Sabbatini R, Porta C, Procopio G (2009) Use of tyrosine kinase inhibitors (TKI) in hemodialitic metastatic renal cell carcinoma patients. Eur Urol 8:185 (Abstract 258)

43.

Calvani N, Morelli F, Leo S et al (2012) Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol 29(3):1908–1913

44.

Protzel C, Ruppin S, Klebingat KJ et al (2008) Sorafenib for the treatment of metastatic renal cell carcinoma with chronic renal failure. Onkologie 31(Supp 1):PE591

45.

Maroto P, Villavicencio H (2008) Sorafenib: tolerance in Patients on Chronic Hemodialysis. Oncology 74:245–246CrossRef

46.

Hilger RA, Richly H, Grubert M et al (2009) Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther 47:61–64PubMed

47.

Ruppin S, Protzel C, Klebingat KJ et al (2009) Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur Urol 55:986–988; quiz 988

48.

Bellmunt J, Eisen T, Fishman M et al (2011) Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 78:24–32PubMedCrossRef

49.

Szczylik C, Cella D, Eisen T et al (2008) Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-{alpha} (IFN). ASCO Meeting Abstracts 26:9603

Title: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor
Authors: F. J. Afonso
U. Anido
O. Fernández-Calvo
S. Vázquez-Estévez
L. León
M. Lázaro
M. Ramos
L. Antón-Aparicio
Publication date: 01-06-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 6/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0985-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer

Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials

Is it necessary to dissect the lymph nodes around an abnormal hepatic artery in D2 lymphadenectomy for gastric cancer?

Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey

Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes

Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer